Edwards Lifesciences Corp (EW)

Conclusion

Edwards Lifesciences develops and sells products for advanced cardiovascular disease, centred on transcatheter heart valves under the SAPIEN, PASCAL and EVOQUE brands, plus surgical structural heart products. At a price of 104.71 USD on 2026-11-09, the market capitalisation is 60.4 billion USD and the enterprise value is 57.9 billion USD.

The verdict is overvalued. The fair value band runs from 61.55 to 92.32 USD with a midpoint of 76.94 USD, giving a margin of safety of -26.5% at the current price. The P/E of 59.1 sits above its ten-year median of 45.4 (a premium of 30.2%), and EV/EBITDA of 49.0 sits above its median of 33.1 (a premium of 48.2%). The discounted cash flow gives 49.91 USD per share at a discount rate of 9.03%, while the fair value from historical multiples is 103.97 USD. The reverse DCF implies growth of 17.4% a year, close to the 17.4% free cash flow per share compound growth of the last five years, while revenue compounded at 6.7% over the same period.

The case rests on the balance sheet and cash generation. The company holds net cash, with net debt to EBITDA of -2.04, an Altman Z-score of 14.08 and interest coverage of 51.7x. The case would weaken on profitability: ROIC is 10.4% against a WACC of 9.0%, the operating margin is 20.8% against a ten-year median of 28.5%, and free cash flow conversion over five years was only 47.7%.

Financial health

Financial health is green, held up by all four balance sheet measures assessed good. The company has net cash, with net debt to EBITDA of -2.04, a current ratio of 4.60 and a quick ratio of 2.57, and debt to equity is only 0.065. Interest coverage of 51.7x leaves ample room for debt service. The Altman Z-score of 14.08 falls in the safe zone; the model was built for manufacturers, and Edwards is one. Insolvency risk: low, about 0.04% by the estimate of the Ohlson model over one to two years, based on figures as of 2025-12-31. Debt has also fallen over five years, with a change of -6.4% a year in the five-year debt versus revenue comparison, so the balance sheet has been getting lighter rather than heavier.

Earnings quality

Earnings quality is yellow: the Beneish reading and the buybacks are favourable, but cash conversion is weak over the longer run. Free cash flow conversion is 139.4% on a trailing basis but only 47.7% over five years, which makes the trailing figure look like a single strong year rather than a trend. Accruals are negative at -3.9%, which is a supportive sign. Stock-based compensation is 2.6% of revenue, leaving free cash flow after it at 1.25 billion USD. The share count fell at a compound rate of 1.5% over five years, indicating net buybacks. The Piotroski score is 6 of 9, and the Beneish M-score of -2.48 is in the unlikely range for manipulation. The company beat earnings estimates in 7 of the last 8 quarters, with an average surprise of 6.9%. Estimate revisions are flat for the current year and the next-year EPS estimate moved only 0.2% over 90 days.

Profitability

Profitability is yellow. Gross margin is 78.1% against a ten-year median of 75.9%, which is a strength. Operating margin is 20.8% against a median of 28.5%, and net margin is 15.3% against a median of 21.4%, so both have fallen well below their history. Operating margin has been fairly stable, with a volatility measure of 7.1%. The key number is return on capital: ROIC is 10.4% against a WACC of 9.0%, a ROIC minus WACC value of 1.4%, which is neutral. The five-year median ROIC was 22.3%, so the spread over the cost of capital has narrowed sharply. Return on equity is 9.4%. The DuPont split shows the return is not inflated by leverage: the equity multiplier is 1.33 and the net margin of 17.7% and asset turnover of 0.44 (both as of 2025-12-31) drive the result.

Growth

Growth is green, with two measures good and two neutral. Revenue compound growth is 4.1% over three years, 6.7% over five years and 9.3% over ten years, so growth has slowed recently. Earnings per share fell 9.1% a year over three years, recovered to 7.1% over five years and reached 9.4% over ten years. Free cash flow per share has grown faster than revenue, at 14.3% over three years, 17.4% over five years and 13.0% over ten years. Revenue grew in 9 of the 10 comparable years, which is consistent. The consensus next-year EPS growth estimate is 12.8%, which is a positive signal, though it is an estimate and not a delivered result.

Valuation

Valuation is red. Every multiple sits above or near its ten-year median except price-to-free-cash-flow and price-to-book: P/E of 59.1 against a median of 45.4 (premium 30.2%), EV/EBITDA of 49.0 against 33.1 (premium 48.2%), price to sales of 9.04 against 8.98 (premium 0.7%), price to free cash flow of 42.4 against 52.6 (discount 19.4%) and price to book of 5.6 against 9.0 (discount 38.2%). The discounted cash flow gives 49.91 USD per share at a discount rate of 9.03%, with growth of 9.3% in the first stage and 2.5% in the terminal stage. The fair value from historical multiples is 103.97 USD. The fair value band of 61.55 to 92.32 USD is an order-of-magnitude estimate built on fixed assumptions, a 5% equity risk premium and capped growth, not a price target. The reverse DCF implies growth of 17.4%, against 6.7% revenue growth and 17.4% free cash flow per share growth over five years. The company pays no dividend.

Risks

The main risk is that the price assumes growth the business has not delivered at the revenue level: revenue grew 4.1% over three years, against the 17.4% implied by the reverse DCF. If margins stay below their ten-year medians, the operating margin of 20.8% against 28.5% limits how much free cash flow the company can generate. ROIC of 10.4% barely exceeds WACC of 9.0%, so further margin pressure could push returns to the cost of capital. Weak five-year free cash flow conversion of 47.7% means earnings have not always turned into cash. Losing the balance sheet strength would matter less than these, given net cash and low insolvency risk. Values not available: the analysis has no debt maturity schedule and no revenue by segment, so product-line concentration and the timing of debt repayments cannot be assessed. The fair value figures rest on fixed assumptions and are not forecasts.